Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
One model of estrogen deficiency in rodents is the aromatase-knockout (ArKO) mouse.
|
15314222 |
2004 |
Oestrogen deficiency
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in CYP19 can result in estrogen deficiency that will influence adult height to certain extent.
|
16733710 |
2006 |
Oestrogen deficiency
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.
|
17547681 |
2007 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
The generation of the aromatase knockout (ArKO) and estrogen receptor knockout (ERKO) mouse models has enabled researchers to characterize the effects of complete estrogen deficiency within the brain and hence behavior.
|
19401953 |
2009 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report that estrogen deficiency in mice caused by targeted disruption of the aromatase gene results in a significant inhibition of telomerase maintenance of telomeres in mouse ovaries in a tissue-specific manner.
|
21574023 |
2011 |
Oestrogen deficiency
|
0.400 |
GermlineCausalMutation
|
disease |
ORPHANET |
Aromatase deficiency owing to a functional variant in the placenta promoter and a novel missense mutation in the CYP19A1 gene.
|
21521281 |
2011 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further clinical studies seem acceptable and are needed to confirm the safety and efficacy of E4 for the breast in hormone replacement therapy, including hormone replacement therapy in women who have or have had BC, especially in those BC patients treated with aromatase inhibitors and suffering from serious complaints due to estrogen deficiency.
|
24997853 |
2014 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, our results strongly suggest that deregulation of miR-320a/RUNX2/CYP11A1 (CYP19A1) cascade plays an important role in the development of estrogen deficiency in human CCs.
|
27965096 |
2017 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, male mice with estrogen deficiency showed same anti-depressive response to duloxetine treatments as aromatase transgenic mice.
|
29163055 |
2017 |
Oestrogen deficiency
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency.
|
29794680 |
2018 |
Oestrogen deficiency
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency.
|
29794673 |
2018 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
More recently, the role of estrogen in men was uncovered by prismatic examples of estrogen deficiency in male patients and by knockout of the estrogen receptor and aromatase in animals.
|
30566601 |
2019 |
Oestrogen deficiency
|
0.400 |
Biomarker
|
disease |
BEFREE |
In postmenopausal women, the neutral effect of aromatase inhibition is likely explained by pre-existing estrogen deficiency.
|
30920620 |
2019 |